Business
Full interview: Fujifilm Diosynth CEO discusses new Holly Springs plant
Martin Meeson, chief executive of Fujifilm Diosynth Biotechnologies, discusses why the company chose Holly Springs for a $2 billion vaccine plant.
Details
Transcript
Martin Meeson, chief executive of Fujifilm Diosynth Biotechnologies, discusses why the company chose Holly Springs for a $2 billion vaccine plant.
Reporter : Adam OwensPhotographer : Luke Notestine
Web Editor : Matthew Burns
Posted 2021-10-14T16:23:05-0400 - Updated 2021-10-14T16:27:11-0400
